REXULTI

REXULTI®

(brexpiprazole)

25 Feb, 2020

Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study

Download REXULTI Clinical Summary – Fleischacker et al

REXULTI Clinical Summary – Fleischacker et al

1-4

Body

REXULTI PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia
Body

Please review Approved Product Information before prescribing.
Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:

REXULTI PI

REXULTI^® is a registered trademark of H. Lundbeck A/S. REXULTI^® is co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.